Letters Section Editor: Robert M. Golub, MD, Senior Editor.
In Reply: Dr Ruck and colleagues propose the use of PCCs and their national database, TESS, as a tool for postmarketing drug surveillance. I have long thought that PCCs are an underused resource for the study of dose-related adverse drug reactions.1 After all, what better way to study such reactions than in an overdose setting? However, it is important to place this in proper perspective.
Strom BL. Drug Safety Monitoring—Reply. JAMA. 2006;296(13):1590. doi:10.1001/jama.296.13.1590-b
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.